Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE <b>Purpose:</b> Unmutated (UM) immunoglobulin heavy chain variable region (IgHV) status or IgHV3-21 gene usage is associated with poor prognosis in chronic lymphocytic leukemia (CLL) patients. 29945996 2018
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 GeneticVariation disease BEFREE A significantly lower usage of IGHV1-69 and IGHV1-2 was documented, with comparable IGHV3-21 frequency (3% Chinese vs 3.8% Italian CLL). 26943037 2016
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL. 25634617 2015
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 GeneticVariation disease BEFREE Clinically, co-occurrence of SF3B1 mutations and subset 2 BCR configuration prompts disease progression in IGHV3-21-CLL, whereas cooperation between NOTCH1 mutations, +12, and subset 8 BCR configuration invariably primes CLL transformation into Richter syndrome. 23637131 2013
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease ORPHANET Clinically, co-occurrence of SF3B1 mutations and subset 2 BCR configuration prompts disease progression in IGHV3-21-CLL, whereas cooperation between NOTCH1 mutations, +12, and subset 8 BCR configuration invariably primes CLL transformation into Richter syndrome. 23637131 2013
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE Scandinavian patients with CLL have shown an overrepresentation of the poor-prognostic IGHV3-21 gene. 22464020 2012
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease ORPHANET To investigate the IGHV3-21 frequency and the clinical impact of IGHV3-21 stereotypy, 337 newly diagnosed Swedish CLL patients from a population-based cohort were analyzed. 22464020 2012
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease ORPHANET T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients. 22875913 2012
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE Our data also provided new evidence supporting the prognostic relevance of separate IGHV genes or stereotyped BCR in CLL, namely: (a) a restricted non-mutated (UM) IGHV gene repertoire in CLL patients with autoimmune haemolytic anaemia (AIHA) (more frequent expression of UM IGHV1-69, IGHV3-11 and IGHV4-59 genes, P = 0.001), a shorter period of AIHA development for expressors of these genes (P = 0.001) and a tendency towards expression of a stereotypic HCDR3 (P = 0.029), (b) a high incidence of second solid tumour development in IGHV3-21-expressing patients (P = 0.005) and (c) differences in overall survival (OS) of UM CLL patients depending on the BCR structure. 21503826 2012
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease ORPHANET IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. 21372840 2011
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE Chronic lymphocytic leukemia (CLL) cells that use IgH encoded by IGHV3-21 and that have a particular stereotypic third CDR (HCDR3), DANGMDV (motif-1), almost invariably express Ig L chains (IgL) encoded by IGLV3-21, whereas CLL that use IGHV3-21-encoded IgH with another stereotypic HCDR3, DPSFYSSSWTLFDY (motif-2), invariably express κ-IgL encoded by IGKV3-20. 21525382 2011
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE We here investigated the prognostic impact of LPL expression in relation to other prognostic markers including IGHV3-21 usage in 140 CLL patients. 19709746 2010
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 PosttranslationalModification disease BEFREE Here, we analyzed the global methylation profiles in CLL, by applying high-resolution methylation microarrays (27,578 CpG sites) to 23 CLL samples, belonging to the immunoglobulin heavy-chain variable (IGHV) mutated (favorable) and IGHV unmutated/IGHV3-21 (poor-prognostic) subsets. 19897574 2010
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE Altogether, we show that TCL1 mRNA expression may predict clinical outcome in CLL and that the IGHV3-21 subset, regardless of mutational status, displays high TCL1 expression. 19889012 2010
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 AlteredExpression disease BEFREE Regarding clinical outcome: (i) UM CLL from the IGHV1-2/1-3/1-18/1-46/7-4-1/IGKV1-39 cluster had poorer prognosis than UM/M cases, or UM cases using the same IGHV genes but not in clusters; (ii) M CLL from the IGHV3-21/IGLV3-21 cluster had TTT similar to UM CLL, and shorter than M CLL expressing IGHV3-21 but not in cluster. 19036101 2009
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. 18326815 2008
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE Moreover, GEP of 7 homHCDR3 versus 6 nonhomHCDR3-IGHV3-21 CLLs yielded 20 differentially expressed genes, with WNT-16 being that expressed at the highest levels in homHCDR3-IGHV3-21 CLLs. 17148579 2007
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE A striking exception to this rule was identified in CLL IGHV3-21-expressing cases: one amino acid was deleted from the CDR2 region in 16/63 (25.4%) mutated CLL IGHV3-21 sequences (including public database-derived IGHV3-21 CLL cases + the present series) vs. only 2/257 (0.78%) public database-derived mutated non-CLL IGHV3-21 sequences; 15/16 CLL IGHV3-21 sequences carrying this deletion belonged to a subset with unique, shared HCDR3 and light chain CDR3 motifs. 16783849 2006
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 AlteredExpression disease LHGDN The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL. 15466924 2005
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 GeneticVariation disease BEFREE Subsets with "CLL-biased" homologous complementarity-determining region 3 (CDR3) were identified: (1) IGKV2-30-IGKJ2, 7 sequences with homologous kappa CDR3 (KCDR3), 5 of 7 associated with homologous IGHV4-34 heavy chains; (2) IGKV1-39/1D-39-IGKJ1/4, 4 unmutated sequences with homologous KCDR3, 2 of 4 associated with homologous IGHV4-39 heavy chains; (3) IGKV1-5-IGKJ1/3, 4 sequences with homologous KCDR3, 2 of 4 associated with unmutated nonhomologous IGHV4-39 heavy chains; (4) IGLV1-44-IGLJ2/3, 2 sequences with homologous lambda CDR3 (LCDR3), associated with homologous IGHV4-b heavy chains; and (5) IGLV3-21-IGLJ2/3, 9 sequences with homologous LCDR3, 3 of 9 associated with homologous IGHV3-21 heavy chains. 16076869 2005
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease CTD_human Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. 15817677 2005
Entrez Id: 28444
Gene Symbol: IGHV3-21
IGHV3-21
0.600 Biomarker disease BEFREE The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL. 15466924 2005